Clinical Trials Search
Clinical Trial 18382
Study Type: Treatment
Phase of Study: Phase I
- David Sallman
A Phase 1 Study of KB003 in Patients with Previously Treated Chronic Myelomonocytic Leukemia (CMML)
The purpose of this study is to determine if KB003 is safe in participants with a blood cancer called Chronic Myelomonocytic Leukemia, (CMML), and to determine the best dose level of study drug to be tested in a larger number of participants. This study will also look at any possible effect that KB003 may have on CMML.
Primary Objectives: The primary objective is to evaluate the safety profile and determine the recommended Phase 2 dose (RP2D) of KB003 in patients with previously treated CMML. Secondary Objectives: To assess preliminary efficacy of KB003 in patients with previously treated CMML. To evaluate the PK and immunogenicity of KB003 in patients with previously treated CMML.